palliative-care-2018-posters-abstracts

4 / 36

Page 59
Notes:
Journal of Palliative Care & Medicine | ISSN: 2165-7386 | Volume 8
August 27-28, 2018 | Boston, USA
4th International Conference on
Palliative Care, Medicine and Hospice Nursing
Electronic medical orders for life-sustaining treatment (eMOLST) in new york state: Length of stay,
direct costs
Claudia R DiBlasi
Touro College, USA
In the United States, approximately 20% of patients die during a hospitalization having an ICU stay with critical care costs
exceeding $82 billion annually, accounting for 13% of inpatient hospital costs. Treatment of sepsis is listed as the most
expensive condition in US hospitals, costing more than $20 billion annually. No study to date has looked at the effect of
palliative care and advanced care planning on intensive care unit (ICU) costs in the short term and long term using direct
variable, direct fixed and indirect ICU costs. Electronic medical orders for life-sustaining treatment (eMOLST), following the
POLST paradigm, is carried out in New York State. Our aim was to investigate the impact of signing an eMOLST form on
the length of stay and direct costs in the intensive care unit. Outcome measures of this retrospective chart included length of
hospital stay, total direct costs, ICU costs, and palliative care consultation for patients >65 years of age, admitted into the ICU
and having a diagnosis of sepsis. Independent samples t-test were used to test for significant differences between those who had
and not signed the eMOLST form on total direct costs, ICU costs, and length of stay in the hospital. Patients who signed the
eMOLST form had significantly higher total direct and ICU costs and had a significantly longer length of hospital stay. Signing
an eMOLST form does not have a positive fiscal impact on direct hospital costs or reduce the overall length of patient stay.
Biography
Claudia R DiBlasi is a doctoral candidate, OMS-4, from TouroCOM-NY-Middletown. She has a Master of Arts in Mathematics from Villanova University. She has
expertise in product management and fulfilled actuarial and analyst responsibilities prior to her transition into the healthcare industry.
Claudia R DiBlasi, J Palliat Care Med 2018, Volume 8
DOI: 10.4172/2165-7386-C3-021